Current outcome of HLA identical sibling versus unrelated donor transplants in severe aplastic anemia: An EBMT analysis

Haematologica

Volumn 100, Issue 5, 2015, Pages 696-702

  Bacigalupo, Andrea ^a   Socie, Gerard ^b   Hamladji, Rose Marie ^c   Aljurf, Mahmoud ^d   Maschan, Alexei ^e   Kyrcz Krzemien, Slawomira ^f   Cybicka, Alicja ^g   Sengelov, Henrik ^h   Unal, Ali ⁱ   Beelen, Dietrich ^j   Locasciulli, Anna ^k   Dufour, Carlo ^l   Passweg, Jakob R ^m   Oneto, Rosi ^a   Signori, Alessio ⁿ   Marsh, Judith C W ^o  

^a UNIVERSITY OF GENOA   (Italy)

^b SAINT LOUIS HOSPITAL   (France)

^c Centre Pierre et Marie Curie   (Algeria)

^d KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^e Oncology and Immunology   (Russian Federation)

^f MEDICAL UNIVERSITY OF SILESIA   (Poland)

^g WROCLAW MEDICAL UNIVERSITY   (Poland)

^h University Hospital ^*  (Denmark)

ⁱ BMT Center   (Turkey)

^j UNIVERSITY HOSPITAL ESSEN   (Germany)

^k SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^l G GASLINI INSTITUTE   (Italy)

^m UNIVERSITY HOSPITAL BASEL   (Switzerland)

ⁿ UNIVERSITY OF GENOA   (Italy)

^o KING'S COLLEGE LONDON   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; FLUDARABINE; THYMOCYTE ANTIBODY; HLA ANTIGEN;

ADULT; APLASTIC ANEMIA; ARTICLE; BONE MARROW; CHRONIC GRAFT VERSUS HOST DISEASE; CONTROLLED STUDY; ENGRAFTMENT; FEMALE; FOLLOW UP; HLA MATCHING; HLA SYSTEM; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL COUNT; ORGAN DONOR; OUTCOME ASSESSMENT; RADIATION DOSE; SURVIVAL PREDICTION; T CELL DEPLETION; VEIN OCCLUSION; WHOLE BODY RADIATION; ADVERSE EFFECTS; ALLOTRANSPLANTATION; ANEMIA, APLASTIC; EUROPE; GENETICS; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; MORTALITY; PROCEDURES; RISK FACTOR; SIBLING; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME; UNRELATED DONORS;

ANEMIA, APLASTIC; EUROPE; FEMALE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA ANTIGENS; HUMANS; INCIDENCE; MALE; RISK FACTORS; SIBLINGS; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; UNRELATED DONORS;

EID: 84929151714     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2014.115345     Document Type: Article

References (20)

1. Dufour C, Svahn J, Bacigalupo A, on behalf of the Severe Aplastic Anemia-Working Party of the EBMT. Front-line immunosuppressive treatment of acquired aplastic anemia. Bone Marrow Transplant. 2013;48(2):174-177.
2. Bacigalupo A, Marsh JC. Unrelated donor search and unrelated donor transplantation in the adult aplastic anaemia patient aged 18-40 years without an HLA-identical sibling and failing immunosuppression. Bone Marrow Transplant. 2013;48(2):198-200.
3. Deeg HJ, Amylon ID, Harris RE, et al. Marrow transplants from unrelated donors for patients with aplastic anemia: minimum effective dose of total body irradiation. Biol Blood Marrow Transplant. 2001;7(4):208-215.
4. Kojima S, Matsuyama T, Kato S, et al. Outcome of 154 patients with severe aplastic anemia who received transplants from unrelated donors: the Japan Marrow Donor Program. Blood. 2002;100(3):799-803.
5. Bacigalupo A, Locatelli F, Lanino E, et al. Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation. Fludarabine, cyclophosphamide and anti-thymocyte globulin for alternative donor transplants in acquired severe aplastic anemia: a report from the EBMT-SAA Working Party. Bone Marrow Transplant. 2005;36(11):947-950.
6. Maury S, Balere-Appert ML, Chir Z, et al. French Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC). Unrelated stem cell transplantation for severe acquired aplastic anemia: improved outcome in the era of high-resolution HLA matching between donor and recipient. Haematologica. 2007;92(5):589-596.
7. Viollier R, Socié G, Tichelli A, et al. Recent improvement in outcome of unrelated donor transplantation for aplastic anemia. Bone Marrow Transplant. 2008;41(1):45-50.
8. Kennedy-Nasser AA, Leung KS, Mahajan A, et al. Comparable outcomes of matchedrelated and alternative donor stem cell transplantation for pediatric severe aplastic anemia. Biol Blood Marrow Transplant 2006;12(12):1277-1284.
9. Bacigalupo A, Socie' G, Lanino E, et al; Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation. Fludarabine, cyclophosphamide, antithymocyte globulin, with or without low dose total body irradiation, for alternative donor transplants, in acquired severe aplastic anemia: a retrospective study from the EBMT-SAA working party. Haematologica. 2010;95(6):976-982.
10. Marsh JC, Gupta V, Lim Z, et al. Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft versus host disease after allogeneic stem cell transplantation for acquired aplastic anemia Blood. 2011;118(8):2351-2357.
11. Samarasinghe S, Steward C, Hiwarkar P, et al. Excellent outcome of matched unrelated donor transplantation in paediatric aplastic anaemia following failure with immunosuppressive therapy: a United Kingdom multicentre retrospective experience. Br J Haematol. 2012;157(3):339-346.
12. Locasciulli A, Oneto R, Bacigalupo A, et al On behalf of the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation (SAAWP, BMT). Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: a report from the European Group for Blood and Marrow Transplantation (EBMT). Haematologica. 2007;92(1):11-18.
13. Sangiolo D, Storb R, Deeg HJ, et al. Outcome of allogeneic hematopoietic cell transplantation from HLA-identical siblings for severe aplastic anemia in patients over 40 years of age. Biol Blood Marrow Transplant. 2010;16(10):1411-1418.
14. Gupta V, Eapen M, Brazauskas R, et al. Impact of age on outcomes after bone marrow transplantation for acquired aplastic anemia using HLA-matched sibling donors. Haematologica. 2010;95(12):2119-2125.
15. Sorror ML, Leisenring W, Deeg HJ, Martin PJ, Storb R. Twenty-year follow-up in patients with aplastic anemia given marrow grafts from HLA-identical siblings and randomized to receive methotrexate/cyclosporine or methotrexate alone for prevention of graft-versushost disease. Biol Blood Marrow Transplant. 2005;11(7):567-568.
16. Champlin RE, Perez WS, Passweg JR, et al. Bone marrow transplantation for severe aplastic anemia: a randomized controlled study of conditioning regimens. Blood. 2007;109(10):4582-4585.
17. Schrezenmeier H, Passweg JR, Marsh JC, et al. Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemia. Blood. 2007;110(4):1397-1400.
18. Bacigalupo A, Socié G, Schrezenmeier H, et al For the Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation (WPSAA-EBMT). Bone marrow versus peripheral blood matched sibling transplants, in acquired aplastic anemia: survival advantage for marrow in all age groups. Haematologica, 2012;97(8):1142-1148.
19. Eapen M, Le Rademacher J, Antin JH, et al. Effect of stem cell source on outcomes after unrelated donor transplantation in severe aplastic anemia. Blood. 2011;118(9):2618-2621.
20. Chen J, Lee V, Luo CJ, et al. Allogeneic stem cell transplantation for children with acquired severe aplastic anaemia: a retrospective study by the Viva-Asia Blood and Marrow Transplantation Group. Br J Haematol. 2013;162(3):383-391.